Search by PDB author

REFINED X-RAY CRYSTAL STRUCTURES OF THE REACTIVE SITE MODIFIED OVOMUCOID INHIBITOR THIRD DOMAINS FROM SILVER PHEASANT (OMSVP3(ASTERISK)) AND FROM JAPANESE QUAIL (OMJPQ3(ASTERISK))
Descriptor:	OVOMUCOID THIRD DOMAIN CLEAVED RDI
Authors:	Musil, D, Bode, W.
Deposit date:	1991-05-13
Release date:	1993-01-15
Last modified:	2024-06-05
Method:	X-RAY DIFFRACTION (1.55 Å)
Cite:	*Refined X-ray crystal structures of the reactive site modified ovomucoid inhibitor third domains from silver pheasant (OMSVP3) and from Japanese quail (OMJPQ3).* J.Mol.Biol., 220, 1991

REFINED X-RAY CRYSTAL STRUCTURES OF THE REACTIVE SITE MODIFIED OVOMUCOID INHIBITOR THIRD DOMAINS FROM SILVER PHEASANT (OMSVP3(ASTERISK)) AND FROM JAPANESE QUAIL (OMJPQ3(ASTERISK))
Descriptor:	OVOMUCOID THIRD DOMAIN CLEAVED RDI
Authors:	Musil, D, Bode, W.
Deposit date:	1991-05-13
Release date:	1993-01-15
Last modified:	2024-06-05
Method:	X-RAY DIFFRACTION (2.5 Å)
Cite:	*Refined X-ray crystal structures of the reactive site modified ovomucoid inhibitor third domains from silver pheasant (OMSVP3) and from Japanese quail (OMJPQ3).* J.Mol.Biol., 220, 1991

Zinc-dependent bifunctional nuclease
Descriptor:	2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ADENINE, Endonuclease 2, ...
Authors:	Chou, T.L, Ko, T.P, Ko, C.Y, Shaw, J.F, Wang, A.H.J.
Deposit date:	2013-01-18
Release date:	2013-04-17
Last modified:	2023-11-08
Method:	X-RAY DIFFRACTION (1.76 Å)
Cite:	Mechanistic insights to catalysis by a zinc-dependent bi-functional nuclease from Arabidopsis thaliana BIOCATAL AGRIC BIOTECHNOL, 2013

Crystal structure of JMJD2A complexed with 3,4-dihydroxybenzoic acid
Descriptor:	3,4-DIHYDROXYBENZOIC ACID, CHLORIDE ION, Lysine-specific demethylase 4A, ...
Authors:	Fang, W.-K, Yang, S.-M, Wang, W.-C.
Deposit date:	2021-05-04
Release date:	2022-05-18
Last modified:	2023-11-29
Method:	X-RAY DIFFRACTION (2.6 Å)
Cite:	Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer. J.Biomed.Sci., 29, 2022